Ligand- and Structure-Based Drug Design and Optimization using KNIME

被引:13
|
作者
Mazanetz, Michael P. [1 ,2 ]
Goode, Charlotte H. F. [2 ]
Chudyk, Ewa, I [3 ]
机构
[1] NovaData Solut Ltd, POB 639, Abingdon On Thames OX14 9JD, Oxon, England
[2] Univ Aberdeen, Dept Chem, Meston Bldg, Aberdeen AB24 3UE, Scotland
[3] Vertex Pharmaceut Europe Ltd, Modeling & Informat, 86-88 Jubilee Ave,Milton Pk, Abingdon On Thames, England
关键词
Hit expansion; virtual screening; predictive toxicology; ligand optimisation; data mining; KNIME; ADME modelling; big data; workflows; computer-aided drug design; WEB SERVICE INFRASTRUCTURE; DEVELOPMENT KIT CDK; SOURCE [!text type='JAVA']JAVA[!/text] LIBRARY; APPROVED DRUGS; HOMOLOGY MODEL; DATABASE; IDENTIFICATION; CHEMISTRY; INFORMATION; FRAGMENT;
D O I
10.2174/0929867326666190409141016
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In recent years there has been a paradigm shift in how data is being used to progress early drug discovery campaigns from hit identification to candidate selection. Significant developments in data mining methods and the accessibility of tools for research scientists have been instrumental in reducing drug discovery timelines and in increasing the likelihood of a chemical entity achieving drug development milestones. KNIME, the Konstanz Information Miner, is a leading open source data analytics platform and has supported drug discovery endeavours for over a decade. KNIME pro-vides a rich palette of tools supported by an extensive community of contributors to enable ligand and structure-based drug design. This review will examine recent developments within the KNIME platform to support small-molecule drug design and provide a perspective on the challenges and future developments within this field.
引用
收藏
页码:6458 / 6479
页数:22
相关论文
共 50 条
  • [21] Optimization of electrostatic interactions in structure-based drug design.
    Kumpf, RA
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 213 : 367 - COMP
  • [22] Structure-based Ligand Design and the Promise Held for Antiprotozoan Drug Discovery
    Hunter, William N.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (18) : 11749 - 11753
  • [23] The role of structure-based ligand design and molecular modelling in drug discovery
    Tollenaere, JP
    [J]. PHARMACY WORLD & SCIENCE, 1996, 18 (02): : 56 - 62
  • [24] Structure-based drug design
    Henry, CM
    [J]. CHEMICAL & ENGINEERING NEWS, 2001, 79 (23) : 69 - +
  • [25] Structure-based drug design
    Stroud, RM
    [J]. FASEB JOURNAL, 1997, 11 (09): : A839 - A839
  • [26] Structure-Based and Ligand-Based Drug Design for HER 2 Receptor
    Huang, Hung-Jin
    Lee, Kuei-Jen
    Yu, Hsin Wei
    Chen, Chien-Yu
    Hsu, Chih-Ho
    Chen, Hsin-Yi
    Tsai, Fuu-Jen
    Chen, Calvin Yu-Chian
    [J]. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2010, 28 (01): : 23 - 37
  • [27] De Novo Design of Inhibitors of DNA Methyltransferase 1: A Critical Comparison of Ligand- and Structure-Based Approaches
    Prado-Romero, Diana L.
    Saldivar-Gonzalez, Fernanda I.
    Lopez-Mata, Ivan
    Laurel-Garcia, Pedro A.
    Duran-Vargas, Adrian
    Garcia-Hernandez, Enrique
    Sanchez-Cruz, Norberto
    Medina-Franco, Jose L.
    [J]. BIOMOLECULES, 2024, 14 (07)
  • [28] Integrating structure-based and ligand-based approaches for computational drug design
    Wilson, Gregory L.
    Lill, Markus A.
    [J]. FUTURE MEDICINAL CHEMISTRY, 2011, 3 (06) : 735 - 750
  • [29] Structure-based drug design
    Kubinyi, H
    [J]. CHIMICA OGGI-CHEMISTRY TODAY, 1998, 16 (10) : 17 - 22
  • [30] STRUCTURE-BASED DRUG DESIGN
    MONTGOMERY, JA
    NIWAS, S
    [J]. CHEMTECH, 1993, 23 (11) : 30 - 37